NCT00546715

A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects

Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BMS-790052 in Subjects Chronically Infected With Hepatitis C Virus Genotype 1

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 95 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 49 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of daclatasvir in subjects with chronic hepatitis C infection

Conditions

• Chronic Hepatitis C

Interventions

Type	Name	Description
DRUG	Daclatasvir	Oral Solution, Oral, Single Dose
DRUG	Placebo	Oral Solution, Oral, Single Dose

Timeline

• Start date: 2007-11-01
• Primary completion: 2008-05-01
• Completion: 2008-05-01
• First posted: 2007-10-19
• Last updated: 2015-11-18
• Results posted: 2015-09-10

Locations

7 sites across 1 country: United States